Software Firm Certara Sold
Certara’s drug development products include the former Tripos, Pharsight and Simcyp businesses and include products for molecular modeling and simulation, and data visualization and analysis. Arsenal also owns WIRB-Copernicus, which provides regulatory and ethical review services for human research.
New York, NY 12/19/13; San Francisco, CA 12/19/13—Certara, a provider of model-based drug development and data analytics software and consulting services, has been sold by Vector Capital to Arsenal Capital Partners. Financial details were not provided. Certara’s solutions cover the discovery, preclinical and clinical stages of drug development. “Technology-driven informatics models will not only result in more cost effective drug development, but will also serve as the foundation for delivering personalized medicine and clinical care,” stated Dr. Donald A. Deieso, operating partner and co-head of Arsenal’s Healthcare Group.
